LAIR2 and neoplasm: This new CAR design combines targeting of CD70 on tumors (34, 39), enhancement of T cell tumor trafficking via expression of the IL-8 receptor (39), and inhibition of LAIR1 by secreting soluble LAIR2 to remodel the immunosuppressive TME (22, 24, 26) (Figure 5, A and B).